Abstract
Although early stage disease detection and treatment options for clear cell renal cell cancer (ccRCC) improved in recent years, prognosis of patients with late stage ccRCC remains poor, mostly due to development of tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors resistance followed by disease progression. Cancer stem cells (ccRCC-CSC) model has focused a significant attention in recent years as a potential explanation for the tumor heterogeneity, drug resistance, disease recurrence and metastasis of ccRCC and other cancers. Cancer stem cells have been proposed to be responsible for tumor initiation, repopulation and growth that cause patients to succumb to renal cancer. Precise identification of ccRCC-CSC populations and definition of hierarchy of cells within ccRCC tumor including tumor initiating cells and tumor progenitor cells will facilitate accurate characterization of drug targets and ultimately contribute to more personalized and effective care. This mini-review discusses the potential strategies to inhibit the signaling pathways underlying stemness in an effort to treat renal cancer. Mechanism that could be exploited as a therapeutic target against drug resistant ccRCC-CSCs is summarized.
Keywords: Cancer stem cells, CD105, CD133, clear cell, CXCR4, IL-15, RCC, renal cancer.
Current Signal Transduction Therapy
Title:Renal Cell Carcinoma Cancer Stem Cells as Therapeutic Targets
Volume: 8 Issue: 3
Author(s): Anna M. Czarnecka and Cezary Szczylik
Affiliation:
Keywords: Cancer stem cells, CD105, CD133, clear cell, CXCR4, IL-15, RCC, renal cancer.
Abstract: Although early stage disease detection and treatment options for clear cell renal cell cancer (ccRCC) improved in recent years, prognosis of patients with late stage ccRCC remains poor, mostly due to development of tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors resistance followed by disease progression. Cancer stem cells (ccRCC-CSC) model has focused a significant attention in recent years as a potential explanation for the tumor heterogeneity, drug resistance, disease recurrence and metastasis of ccRCC and other cancers. Cancer stem cells have been proposed to be responsible for tumor initiation, repopulation and growth that cause patients to succumb to renal cancer. Precise identification of ccRCC-CSC populations and definition of hierarchy of cells within ccRCC tumor including tumor initiating cells and tumor progenitor cells will facilitate accurate characterization of drug targets and ultimately contribute to more personalized and effective care. This mini-review discusses the potential strategies to inhibit the signaling pathways underlying stemness in an effort to treat renal cancer. Mechanism that could be exploited as a therapeutic target against drug resistant ccRCC-CSCs is summarized.
Export Options
About this article
Cite this article as:
Czarnecka M. Anna and Szczylik Cezary, Renal Cell Carcinoma Cancer Stem Cells as Therapeutic Targets, Current Signal Transduction Therapy 2013; 8 (3) . https://dx.doi.org/10.2174/1574362409666140206222251
DOI https://dx.doi.org/10.2174/1574362409666140206222251 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry Emerging Therapies in Chronic Myeloid Leukemia
Current Cancer Drug Targets Targeting Hypoxia-Inducible Factor-1 (HIF-1) Signaling in Therapeutics: Implications for the Treatment of Inflammatory Bowel Disease
Recent Patents on Inflammation & Allergy Drug Discovery B7-H3 Immune Checkpoint Protein in Human Cancer
Current Medicinal Chemistry Selectively Targeted Anti-Neoplastic Cytotoxicity of Three Immunopharmaceuticals with Covalently Bound Fludarabine, Gemcitabine and Dexamethasone Moieties Synthesized Utilizing Organic Chemistry Reactions in a Multi-Stage Regimen
Current Pharmaceutical Design In Vitro and In Vivo Sirolimus for Modulation of Allogeneic Hematopoietic Stem Cell Transplantation
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Selenium Compounds and Apoptotic Modulation: A New Perspective in Cancer Therapy
Mini-Reviews in Medicinal Chemistry Glyco-Nanomaterials: Translating Insights from the “Sugar-Code” to Biomedical Applications
Current Medicinal Chemistry Cardiovascular Effects of EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibodies
Cardiovascular & Hematological Agents in Medicinal Chemistry Activation of Sphingosine Kinase-1 in Cancer: Implications for Therapeutic Targeting
Current Molecular Pharmacology Cisplatin Properties in a Nanobiotechnological Approach to Cancer: A Mini-Review
Current Cancer Drug Targets Role of Netrin-1 Beyond the Brain: From Biomarker of Tissue Injury to Therapy for Inflammatory Diseases
Recent Patents on Biomarkers Inhibition of mTOR Signaling by Quercetin in Cancer Treatment and Prevention
Anti-Cancer Agents in Medicinal Chemistry Antibody Directed Enzyme Prodrug Therapy (ADEPT) and Related Approaches for Anticancer Therapy
Mini-Reviews in Medicinal Chemistry Application of Resveratrol in Diabetes: Rationale, Strategies and Challenges
Current Molecular Medicine New Insights on the Mode of Action of Microcystins in Animal Cells - A Review
Mini-Reviews in Medicinal Chemistry Nonviral Gene Therapy
Current Gene Therapy AGE-RAGE System and Carcinogenesis
Current Pharmaceutical Design Role of Iodine, Selenium and Other Micronutrients in Thyroid Function and Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets The Chaperone-like Activity of Rat HspB8/Hsp22 and Dynamic Molecular Transition Related to Oligomeric Architectures In Vitro
Protein & Peptide Letters